TARS

In the past six months, Tarsus reported strong Q2 2026 XDEMVY net product sales of $173.9 million, a 69% year-over-year increase, leading to raised full-year guidance and a 20% stock gain. In Q3 2026, the company expanded its pipeline by acquiring Alkeus Pharmaceuticals for gildeuretinol (Stargardt disease) and iRenix Medical for IRX-101 (ocular antiseptic). Tarsus also completed an oversubscribed $125.0 million private placement equity financing in August 2026. After a Q1 2026 sales dip, prescription trends rebounded to all-time highs in Q2 2026. A Culper Research short report in July 2026, raising concerns about anti-kickback violations and market potential, caused a temporary 10% stock drop that recovered within three sessions. Positive analyst sentiment and increased price targets, with a 'Moderate Buy' consensus, also influenced stock movements.